Leadership and Management
Dr. Jim Zapf has 25 years of direct experience in developing small molecule therapeutics in the biopharmaceutical industry. His work has resulted in 8 patents and 6 clinical candidates. His area of specific expertise is the use of structure-based drug design and Structure Activity Relationships (SAR) to identify and optimize small molecules for clinical development. In addition to working directly on
Dr. Zapf obtained a
Louis Tommasino, CPA
CFO
Mr. Louis Tommasino has extensive experience in small company start-up, tax services, auditing and financial consulting, including trust and business planning and management services. Since 1996, he’s operated his own CPA practice, providing results-oriented tax and accounting services for small businesses, non-profit organizations, estates and individuals, Mr. Tommasino has accounting experience in a broad range of industries including the biotech industry, entertainment, restaurants, real estate, medical offices, contractors, retailers, medical supplies, and not-for-profit organizations. Mr. Tommasino has worked with several start-up companies in Arizona and California. He also teaches accounting and tax courses at a San Diego community college. He graduated with a bachelor of science in business administration from Arizona State University, which is consistently rated in the top 20 U.S. schools of accountancy. He has worked in government as a controller and in a large accounting firm as an auditing manager.
Dr. Chris A. Buhr, PhD
Advisor
Dr. Chris Buhr has more than 20 years of direct experience in the discovery and development of small molecule therapeutics in Oncology and Inflammation. His work has resulted in 40 patents and applications. He has importantly contributed to 6 Investigational New Drug (IND) applications. As a Director of Medicinal Chemistry at Exilixis Dr. Buhr’s most significant achievement to date was leading the medicinal chemistry program for the discovery and development of XL765. This drug is currently in eleven Phase I and Phase II clinical trials (five completed
Dr. Buhr obtained a
Scientific Advisory Board
David Webb, Ph.D.
Adjunct Professor, Department of Integrative Structural and Computational Biology, The Scripps Research Institute
Dr. Webb is currently Adjunct Professor at The Scripps Research Institute (TSRI). At TSRI, he is currently associated with the laboratory of Professor Ian Wilson that employs structure based drug design to suggest new approaches to drug discovery for important, life threatening viral diseases such as HIV, Influenza and Hepatitis C. From 2011-2014 he was associated with the laboratories of Professors Ray Stevens and Peter Kuhn, that includes studies on the structural biology and pharmacology of G-protein coupled receptors with a focus on receptors that have therapeutic potential (Stevens) and detection of circulating tumor cells (Kuhn). He was Chairman of the Board of Sorrento Therapeutics from 2012-2013 and is also Chairman Emeritus of the Board of BIOCOM (2012), a member of the Executive Committee of the Board of CONNECT, a member of the Board of Directors of the La Jolla Institute of Allergy and Immunology, and a member of the Advisory Council of the College of Science and Mathematics at Cal State University, San Marcos. He currently serves as an advisor/SAB member for several private biotechnology companies.
Dr. Webb joined Celgene-San Diego in
Dr. Webb earned his Ph.D. in Microbiology/Immunology at Rutgers, The State University of New Jersey-New Brunswick, and a BA, MA in Biology from California State University-Fullerton.
Dr. Michael Karin, PhD
Distinguished Professor of Pharmacology and Pathology at the School of Medicine, University of California, San Diego
Dr. Michael Karin received his BSc in Biology in 1975 at Tel Aviv University, Tel Aviv, Israel and his
David W. Anderson, Ph.D.
Biotechnology Consultant
Dr. Anderson is an accomplished leader in medical research & product development with experience as a research scientist, director of research, entrepreneur, & executive leader in the pharmaceutical industry (Searle, Johnson & Johnson, Celgene), biotechnology (Signal/Celgene, Proprius Pharmaceuticals, Cypress Bioscience, Eclipse Therapeutics, and Ignyta), and several academic institutions (University of Colorado, The Scripps Research Institute, Graceland University). He holds a Ph.D. in Medical Microbiology and Immunology from the University of Missouri-Columbia.
He has a successful track record as a leader or member of teams responsible for